Kestra Medical Q4 rev $17.2M (+71%), FY rev $59.8M (+115%); guides FY26 $85M

KESTRA MEDICAL TECHNOLOGIES, LTD.

Q4 revenue $17.2M (+71% YoY); FY25 revenue $59.8M (+115% YoY).
Q4 gross margin 44.3% vs 13.9% prior year; FY gross margin 40.5% vs 1.3%.
Q4 prescriptions: 3,903 (+43% YoY); FY prescriptions: 13,193 (+72% YoY).
FY26 revenue guidance initiated at $85M, representing 42% growth over FY25.
GAAP net loss $51.1M in Q4; adjusted EBITDA loss $20.3M; cash $237.6M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.